Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review

Table 2 Demographics of study cohorts in inflammatory bowel disease

Ref.	Diagnostic	Biological	Number	Female, n (%)	Smoking, n (%)	Previous surgery, n (%)	Previous biological therapy, n (%)	Concomitant medications
								CS, n (%)	IMMs, n (%)	5-ASA, n (%)	Surgical intervention, n (%)	Enteral nutrition, n (%)
Chaparro et al[12], 2018	IBD	ADA/IFX	182	90 (49.5)	50 (27.5)	49 (26.9)	48 (26.4)		63 (34.6)
Ungar et al[28], 2016	IBD	ADA/IFX	145	64 (44.1)	19 (13.1)	33 (22.8)	37 (25.5)	27 (18.6)	79 (54.5)
Yarur et al[29], 2016	IBD	ADA	66	27 (40.9)	6 (9.1)		42 (63.6)	14 (21.2)	21 (31.2
Roblin et al[26], 2014	IBD	ADA	40	22 (55)					5 (12.5)
Morita et al[18], 2016	UC	ADA/IFX	64	25 (39.1)			4 (6.3)	50 (78.1)	34 (53.1)	48 (75.0)
Morita et al[19], 2016	CD	ADA	42	15 (35.7)		18 (42.9)	15 (35.7)	5 (11.9)	24 (57.1)	30 (71.4)
Strik et al[27], 2019	PfCD	ADA	19	9 (47.4)	5 (26.3)		9 (47.4)				4 (21.1)
Plevris et al[24], 2020	PfCD	ADA	35	17 (48.6)	3 (8.6)		21 (60.0)		15 (42.9)
Zittan et al[30], 2016	CD	ADA	60	31 (51.7)	9 (15.0)		36 (60.0)	Total of concomitant therapy: 18 (30.0)
Papamichael et al[20], 2017	UC	ADA	43	20 (46.5)	4/35 (11.4)		38 (88.4)	12 (27.9)	7 (16.3)
Juncadella et al[16], 2018	IBD	ADA	98	60 (61.2)	34 (34.7)	28/72 (38.9)			26 (26.5)
Feng et al[14], 2019	CD	IFX	141	51 (36.2)	5 (3.5)	22 (15.6)	8 (5.7)		20 (14.2)
Papamichael et al[22], 2018	UC	IFX	56	24 (42.9)	11 (19.6)				18 (32.1)
Papamichael et al[21], 2018	CD	IFX	110	51 (46.4)	19 (17.3)	20 (18.2)	8 (7.3)		28 (25.5)
Strik et al[27], 2019	PfCD	IFX	47	29 (61.7)	7 (14.9)		15 (31.9)				13 (27.7)
Plevris et al[24], 2020	PfCD	IFX	29	11 (37.9)	4 (13.8)		1 (3.4)		17 (58.6)
Papamichael et al[23], 2016	UC	IFX	101	37 (36.6)	12 (12.0)		5 (4.9)	36 (35.6)	49 (48.5)
Dreesen et al[31], 2020	CD	IFX	116	68 (58.6)
Imaeda et al[15], 2014	CD	IFX	45	12 (26.7)				8 (17.8)	15 (33.3)	33 (73.3)
EI-Matary et al[32], 2019	PCD	IFX	52	21 (40.4)				33 (63.5)	AZA 17 (32.7);MTX 30 (57.7)	7 (13.5)	15 (28.8)	10 (19.2)
Kang et al[17], 2019	PCD	IFX	105	31 (29.5)			6 (5.7)	6 (5.7)	95 (90.5)
Dreesen et al[13], 2018	IBD	VDZ	179	106 (59.2)	32 (17.9)		153 (85.5)	73 (40.8)	20 (11.2)
Yacoub et al[34], 2018	IBD	VDZ	82	44 (53.7)		18 (22.0)	67 (78.0)	6 (7.3)	13 (15.9)	14 (17.1)
Hanzel et al[33], 2019	IBD	VDZ	51	19 (37.3)	10 (19.6)		43 (84.3)	20 (39.2)	6 (11.8)
Pouillon et al[25], 2019	UC	VDZ	31	13 (41.9)	7 (22.6)		28 (90.3)	12 (38.7)	7 (22.6)	14 (45.2)

IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; IFX: Infliximab; ADA: Adalimumab; VDZ: Vedolizumab; PFCD: Perianal fistula Crohn’s disease; CS: Corticosteroid; IMM: Immunosuppressor; 5-ASA: 5-amino salicylic acid.